Guardant Health Inc.
37.25
-0.85 (-2.23%)
At close: Jan 14, 2025, 3:59 PM
37.46
0.56%
After-hours Jan 14, 2025, 04:00 PM EST
undefined%
Bid 37.5
Market Cap 4.60B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -4.28
PE Ratio (ttm) -8.7
Forward PE n/a
Analyst Strong Buy
Ask 39.79
Volume 2,157,335
Avg. Volume (20D) 1,870,409
Open 38.19
Previous Close 38.10
Day's Range 35.83 - 39.29
52-Week Range 15.81 - 39.29
Beta undefined

About GH

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test fo...

Sector Healthcare
IPO Date Oct 4, 2018
Employees 1,768
Stock Exchange NASDAQ
Ticker Symbol GH

Analyst Forecast

According to 14 analyst ratings, the average rating for GH stock is "Strong Buy." The 12-month stock price forecast is $39, which is an increase of 4.70% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Guardant Health Inc. is scheduled to release its earnings on Feb 20, 2025, during market hours.
Analysts project revenue of $188.92M, reflecting a 21.84% YoY growth and earnings per share of -0.51, making a -20.31% decrease YoY.
1 month ago · Source
+8.42%
Guardant Health shares are trading higher after a ... Unlock content with Pro Subscription
2 months ago · Source
+13.05%
Guardant Health shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 revenue guidance above estimates.